Here's Why Qiagen (QGEN) is a Strong Value Stock

Zacks Equity Research identifies QIAGEN (QGEN), a molecular diagnostics and nucleic acid technology provider, as a strong value stock, meriting a #2 (Buy) Zacks Rank and B-rated VGM and Value Style Scores. This assessment is underpinned by an attractive 19.95 forward P/E, recent upward revisions to its fiscal 2025 earnings estimates by nine analysts to $2.34 per share, and a consistent 4.9% average earnings surprise, positioning QGEN as a notable consideration for investors.

Analysis

QIAGEN N.V. (QGEN) is presented as a compelling investment case, primarily driven by strong quantitative signals within the Zacks rating framework. The company holds a #2 (Buy) rank, complemented by 'B' ratings for both its overall VGM (Value, Growth, Momentum) and specific Value Style Scores. This valuation-centric thesis is supported by a forward P/E ratio of 19.95, which is flagged as attractive. Critically, the outlook for future profitability is improving, as evidenced by nine upward earnings estimate revisions for fiscal 2025 within the last 60 days. This collective analyst sentiment has pushed the consensus earnings estimate for that period up by $0.07 to $2.34 per share. Further reinforcing this positive view is the company's consistent operational performance, demonstrated by an average positive earnings surprise of 4.9% in past reports.

Key Decisions for Investors

• Value-oriented investors should consider QGEN, given its favorable forward P/E of 19.95 and its designation as a #2 (Buy) with a 'B' Value Score.
• The positive trend in earnings revisions, with nine analysts upgrading fiscal 2025 estimates, represents a significant bullish catalyst that warrants monitoring for continued momentum.
• Given the company's track record of a 4.9% average earnings surprise, investors should watch for continued outperformance in upcoming earnings reports as a key validation of the current thesis.